Revenues, Schmevenues. Why Biotech s CEOs Lead the Salary Race | GenomeWeb

NEW YORK, April 2 - Call it a love story born of supply and demand.

Despite their comparatively miniscule revenue base, publicly traded biotech companies, including genomics tool and tech firms, pay their CEOs considerably more than medical instrument or pharmaceutical companies, results of a recent survey show.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.